XERS vs PAHC vs ELAN vs AMRX vs ZTS

For growth investors, Xeris Biopharma Holdings, Inc.

(XERS) is the stronger pick with 43. 7% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). Zoetis Inc. (ZTS) offers the better valuation at 14. 5x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Xeris Biopharma Holdings, Inc. (XERS) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zoetis Inc.

(ZTS) is the cheapest at 14. 5x versus Xeris Biopharma Holdings, Inc. at 2071. 9x. On forward P/E, Zoetis Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 0. 99x versus Phibro Animal Health Corporation's 1. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +163. 8%, compared to -44. 4% for Zoetis Inc. (ZTS). Over 10 years, the gap is even starker: PAHC returned +113. 5% versus XERS's -67. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xeris Biopharma Holdings, Inc.

(XERS) is the lower-risk stock at 0. 87β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 68% more volatile than XERS relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xeris Biopharma Holdings, Inc.

(XERS) is pulling ahead at 43. 7% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, XERS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zoetis Inc.

(ZTS) is the more profitable company, earning 28. 2% net margin versus -4. 9% for Elanco Animal Health Incorporated — meaning it keeps 28. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — XERS leads at 81. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 0. 99x versus Phibro Animal Health Corporation's 1. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Zoetis Inc. (ZTS) trades at 11. 9x forward P/E versus 50. 8x for Xeris Biopharma Holdings, Inc. — 38. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 53. 0% to $133. 57.

In this comparison, ZTS (2.

3% yield), PAHC (1. 1% yield) pay a dividend. XERS, ELAN, AMRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88), 2. 3% yield). Both have compounded well over 10 years (ZTS: +97. 8%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XERS is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock; AMRX is a small-cap quality compounder stock; ZTS is a mid-cap deep-value stock. PAHC, ZTS pay a dividend while XERS, ELAN, AMRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.